Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,980

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Open access
Estes, Chris, Anstee, Quentin M., Arias-Loste, Maria Teresa, Bantel, Heike, Bellentani, Stefano, Caballeria, Joan, Colombo, Massimo, Craxi, Antonio, Crespo, Javier, Day, Christopher P., Eguchi, Yuichiro, Geier, Andreas, Kondili, Loreta A., Kroy, Daniela C., Lazarus, Jeffrey V., Loomba, Rohit, Manns, Michael P., Marchesini, Giulio, Nakajima, Atsushi, Negro, Francesco, Petta, Salvatore, Ratziu, Vlad, Romero-Gomez, Manuel, Sanyal, Arun, Schattenberg, Jörn M., Tacke, Frank, Tanaka, Junko, Trautwein, Christian, Wei, Lai, Zeuzem, Stefan, Razavi, Homie · 2018 · Journal of Hepatology

Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. METHODS: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. RESULTS: If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0-30%), between 2016-2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15-56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. CONCLUSIONS: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. LAY SUMMARY: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2018.05.036

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. Kern B, Newsome P, Karam V, Adam R, Berlakovich G, Fritz J, et al. Nonalcoholic steatohepatitis as indication for liver transplantation in Europe. Do we choose the right organs for the right recipients? American Transplant Conference; 2015 May 4, 2015; Philadelphia, Pennsylvania; 2015.
  2. Marmur, 2010, Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome, Scand J Gastroenterol, 45, 60, 10.3109/00365520903384742 · doi:10.3109/00365520903384742
  3. Huang, 2013, The national program for deceased organ donation in China, Transplantation, 96, 5, 10.1097/TP.0b013e3182985491 · doi:10.1097/tp.0b013e3182985491
  4. Delmonico, 2013, A welcomed new national policy in China, Transplantation, 96, 3, 10.1097/TP.0b013e31829949fb · doi:10.1097/tp.0b013e31829949fb
  5. Wang, 2013, Responses to comments on “Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report”, Hepatobiliary Surg Nutr, 2, 309
  6. Aberg, 2011, Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score, Liver Transpl, 17, 1333, 10.1002/lt.22388 · doi:10.1002/lt.22388

Cited by

See all 1,980

Metadata

Authors
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., Eguchi, Y., Geier, A., Kondili, L. A., Kroy, D. C., Lazarus, J. V., Loomba, R., Manns, M. P., Marchesini, G., Nakajima, A., Negro, F., Petta, S., Ratziu, V., Romero-Gomez, M., Sanyal, A., Schattenberg, J. M., Tacke, F., Tanaka, J., Trautwein, C., Wei, L., Zeuzem, S., & Razavi, H.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2018-10
Volume
69
Issue
4
Pages
896-904
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2806839461
Cited by
1,980
References
60
FWCI
94.09
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.